Zacks Research Forecasts Exelixis’ Q4 Earnings (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) – Equities research analysts at Zacks Research increased their Q4 2026 earnings per share (EPS) estimates for shares of Exelixis in a research note issued to investors on Tuesday, July 1st. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings of $0.76 per share for the quarter, up from their prior estimate of $0.75. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q2 2027 earnings at $0.74 EPS and FY2027 earnings at $2.95 EPS.

Other equities research analysts have also recently issued research reports about the stock. Guggenheim set a $45.00 price target on shares of Exelixis and gave the stock a “buy” rating in a report on Thursday, May 15th. JMP Securities lifted their price target on shares of Exelixis from $47.00 to $50.00 and gave the stock a “market outperform” rating in a report on Monday, June 23rd. HC Wainwright lifted their price target on shares of Exelixis from $47.00 to $53.00 and gave the stock a “buy” rating in a report on Monday, June 30th. Wall Street Zen cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 15th. Finally, Wells Fargo & Company reaffirmed a “market outperform” rating on shares of Exelixis in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average target price of $43.56.

Exelixis Stock Up 3.6%

Shares of NASDAQ EXEL opened at $45.91 on Friday. Exelixis has a twelve month low of $21.86 and a twelve month high of $49.62. The stock’s 50 day moving average price is $41.88 and its 200-day moving average price is $37.65. The company has a market capitalization of $12.52 billion, a PE ratio of 20.87, a PEG ratio of 0.93 and a beta of 0.28.

Hedge Funds Weigh In On Exelixis

A number of large investors have recently made changes to their positions in the company. Frank Rimerman Advisors LLC boosted its stake in shares of Exelixis by 4.7% during the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 285 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Exelixis by 6.1% during the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 307 shares during the period. Balyasny Asset Management L.P. boosted its stake in shares of Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 317 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in shares of Exelixis by 4.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 330 shares during the period. Finally, Rathbones Group PLC boosted its stake in shares of Exelixis by 5.3% during the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company’s stock worth $253,000 after purchasing an additional 347 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Exelixis news, Director Tomas J. Heyman sold 4,544 shares of Exelixis stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total value of $201,253.76. Following the sale, the director directly owned 32,470 shares in the company, valued at approximately $1,438,096.30. The trade was a 12.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 7,535 shares of Exelixis stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total transaction of $324,683.15. Following the completion of the transaction, the director directly owned 358,882 shares of the company’s stock, valued at $15,464,225.38. The trade was a 2.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 458,113 shares of company stock worth $21,024,817. 2.82% of the stock is currently owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.